Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 4/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.31 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29734718 | 1.00 | RXRA (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL17588940 | 0.87 | RXRA (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL4116261 | 0.86 | RXRA (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL29478948 | 0.85 | RXRA (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL21393943 | 0.85 | RXRA (0.38) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL138511 | 0.85 | RXRA (0.37) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL20581028 | 0.84 | RXRA (0.37) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL30858862 | 0.84 | RXRA (0.37) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL29263972 | 0.84 | ALDH1A1 (0.37) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL1141263 | 0.84 | RXRA (0.36) | RXRARXRBRXRGCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109900-A1 | AZABICYCLIC SHP2 INHIBITORS | PROMIDIS S.R.L. (IT) | 2024-04-04 | — | — | US | disclosed |
| EP-4288431-A1 | AZABICYCLIC SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2023-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109900-A1 | AZABICYCLIC SHP2 INHIBITORS | PTPN22, PTPN2, PTPN5 | RXRA 1504/4885RXRB 1096/4885RXRG 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.